TRAT1 and hepatocellular carcinoma: Multiple studies have provided evidence indicating that the expression levels of TRIM family genes are associated with negative clinical outcomes in various types of cancer, including acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic cancer, breast cancer, lung cancer, and GC [6–12].